<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02706821</url>
  </required_header>
  <id_info>
    <org_study_id>WJG-HG-PLE</org_study_id>
    <nct_id>NCT02706821</nct_id>
  </id_info>
  <brief_title>Anti-diabetic Effects of Persimmon Leaf Extract</brief_title>
  <official_title>An Eight-week, Randomized, Double-blind, Placebo-controlled Crossover Clinical Trial of Persimmon Leaf Extract on Anti-diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chonbuk National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chonbuk National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators performed a 8-week, randomized, double-blind, placebo-controlled crossover
      human trial to evaluate the efficacy and safety of persimmon leaf extract on blood glucose.
      The investigators measures changes in diabetes associated parameters, including fasting blood
      glucose, postprandial blood glucose, insulin, C-peptide and HbA1c.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting and postprandial plasma glucose</measure>
    <time_frame>baseline day 57, 85 and 141</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting plasma insulin</measure>
    <time_frame>baseline and day 57, 85 and 141</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-peptide</measure>
    <time_frame>baseline and day 57, 85 and 141</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycated hemoglobin (HbA1c)</measure>
    <time_frame>baseline and day 57, 85 and 141</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adiponectin</measure>
    <time_frame>baseline and day 57, 85 and 141</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>leptin</measure>
    <time_frame>baseline and day 57, 85 and 141</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>resistin</measure>
    <time_frame>baseline and day 57, 85 and 141</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of Inflammation</measure>
    <time_frame>baseline and day 57, 85 and 141</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor necrosis factor alpha (TNF-Î±)</measure>
    <time_frame>baseline and day 57, 85 and 141</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-6 (IL-6)</measure>
    <time_frame>baseline and day 57, 85 and 141</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocyte chemoattractant protein-1 (MCP-1)</measure>
    <time_frame>baseline and day 57, 85 and 141</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Prediabetes</condition>
  <arm_group>
    <arm_group_label>Treatment sequence 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PLE (persimmon leaf extract) once a day during 8 weeks cross-over to placebo once a day during 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment sequence 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo once a day during 8 weeks cross-over to PLE once a day during 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Persimmon leaf extract</intervention_name>
    <description>Persimmon leaf extract (PLE), crossover design</description>
    <arm_group_label>Treatment sequence 1</arm_group_label>
    <arm_group_label>Treatment sequence 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, crossover design</description>
    <arm_group_label>Treatment sequence 1</arm_group_label>
    <arm_group_label>Treatment sequence 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 20-75 years

          -  Fasting blood glucose (FPG) 100~140 mg/dL or postprandial blood glucose (PPG) 140~250
             mg/dL

        Exclusion Criteria:

          -  FPG more than 140 mg/dL

          -  2h PPG more than 200 mg/dL

          -  Type 1 diabetes or HbA1c more than 9.0%

          -  treatment with corticosteroids within the past 4 weeks

          -  cardiovascular disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2016</study_first_submitted>
  <study_first_submitted_qc>March 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2016</study_first_posted>
  <last_update_submitted>March 13, 2016</last_update_submitted>
  <last_update_submitted_qc>March 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chonbuk National University Hospital</investigator_affiliation>
    <investigator_full_name>Soo-Wan Chae</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>prediabetes</keyword>
  <keyword>blood glucose</keyword>
  <keyword>clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

